Allogene Therapeutics ALLO Proceeds from CIRM award (Note 5)
Proceeds from CIRM award (Note 5) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept allo:ProceedsFromGrantAwards.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's proceeds from cirm award (note 5).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's proceeds from CIRM award (note 5)?
- Allogene Therapeutics (ALLO) reported proceeds from CIRM award (note 5) of $0 in Q1 2026.
- How has Allogene Therapeutics's proceeds from CIRM award (note 5) changed year-over-year?
- Allogene Therapeutics's proceeds from CIRM award (note 5) decreased by 100.0% year-over-year, from $3.35M to $0.
- What does proceeds from CIRM award (note 5) mean?
- This represents cash inflows received from government or private research grants, such as those from the California Institute for Regenerative Medicine (CIRM). These funds support clinical development and research initiatives without diluting existing shareholders. It is a key indicator of non-dilutive funding success in the biotech sector.